It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately, most of these are currently projected to deliver a solid 2018.
Disney, Intel, Pfizer, and Verizon led Tuesday's drop in the DJIA.
One area to look at in this overbought and pricey market is pharmaceuticals. These five now are considered to be “deep value” plays at Merrill Lynch.
The October 31 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks decreased.
Merrill Lynch points to five companies that, in their words, should be key players in the young but growing biosimilar market.
When Pfizer released its third-quarter earnings report before the markets opened on Tuesday, the results and guidance lived up to what analysts expected but weren't enough to placate investors.
Chris Lange Pfizer is scheduled to release its third-quarter financial results before the markets open on Tuesday.
Chris Lange The busiest earnings week of the season has come and gone, but there are still plenty more big names stepping into the spotlight this week.
24/7 Wall St. has collected a few pharma and biotech catalysts that are coming up on the calendar in November and December.
The October 13 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Among the most shorted stocks traded on the New York Stock Exchange, two struggling retailers saw notable growth in their short interest in the latest reporting period.
Here are 13 featured spin-offs already underway and potential spin-offs that could be seen in 2017 and into 2018 that could radically change how Wall Street and Main Street evaluate companies ahead.
The September 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The September 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
If there is one cure or one treatment that could be the proverbial Holy Grail for a pharmaceutical or biotech company, it would be in a successful treatment of Alzheimer's disease.
